Key Points – Lilly reported 48% year-over-year revenue growth in Q2 2026, with MOUNJARO and ZEPBOUND generating $14.9 billion in combined sales.
The company raised its full-year revenue outlook to $85 billion–$87 billion and adjusted earnings-per-share guidance to $35.50–$36.50. – Demand for obesity medicines remained strong, with U.S. obesity prescriptions up 78% year over year
Lilly said the Medicare GLP-1 Bridge Program expanded coverage for its obesity medicines by 35%, while Foundayo’s launch continued gaining prescribers and international approvals. – Lilly reported positive Phase III results for experimental medicine retatrutide and plans to seek U.S. approval in the first quarter of 2027. The company also expanded its pipeline through acquisitions in infectious disease, mental health and neuroscience, while investing in new manufacturing facilities. – The FTC Is Suing Hims & Hers Health—Here’s Why Investors Shouldn’t Panic Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered growth across key products and major geographies, advanced its pipeline and added assets through business development.
Lilly said its key products increased by nearly $6.8 billion during the quarter, while its oncology, immunology and neuroscience medicines collectively grew 121% from the prior-year period. – As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner “We delivered strong business results, received regulatory approval for new indications, shared positive phase III trial results, added new medicines to our pipeline, and expanded access to medicines for patients,” Ricks said. Financial performance and updated outlook Chief Financial Officer Lucas Montarce said second-quarter revenue rose 48% from the same period in…